Hepcinat and its combinations

The manufacturer reached his goal: to be these special drugs available for everybody and produced generic brands:

HEPCINAT (Sofosbuvir), HEPCINAT-LP (Ledipasvir / Sofosbuvir), NATDAC (Daclatasvir).

 

The manufacturer is the first among these companies, which started to product these generic variants – Sofosbuvir (SOF), and its combinations in India.

The SOF is a good tolerated, effective antiviral drug, which will open a new era in the oral therapy. The HCF SOF safety and succesfull to use int he periods of different viral genotype diseases. The SOF could be used for every infected patients, and this new dreug must be fit during the treatment for the patient to reach the maximum performance. The Sofosbuvir is really an evolution and revolution int he treatment of HCV.

The Ledipasvir and Sofosbuvir are two products with fix dose and combined , which contain 90 mg of Ledipőasvir and 400 mg of Sofosbuvir in one pill. It is suitable for curing of chronicle Hepatitis C (CHC), genotype 1 infected adults.

 

The Daclatasvir is the first in its category which is applicable combined with NS5A for Sofosbuvir treatment, depending on the chronicle HCV genotype for 3 disease. Comparing with other type of treatments, this combination is not only increases the healing rate, buti t is suitable for the treatment of other complicated HCV patients.

 

The HCV is the main reason of the advanced liver diseases all over the world. The virus bypasses the patients immune system, and that is why it was so difficult to realize it, and to find the safety, simple and reliable oral, antiviral treatment. Int he beginning the interferon and ribavirin cure was used as standard treatment , but the wide spectrum HCV disease treatment was full of excessive and often unpleasant side effects.